By: Krystle Vermes Source: BioSpace From: pharmalive.com Evive Biotech announced today that its Phase III study investigating F-627 to treat chemotherapy-induced neutropenia (CIN) in breast cancer patients has met its primary and secondary endpoints. F-627, also known as efbemalenograstim alpha, works by increasing the production of white blood cells. A low concentration of these cells is a common side effect …
-
-
The True Meaning of Easter
-
Peace for a Breast Cancer Survivor
-
What Would Motivate a Person to Action After a Breast Cancer Diagnosis
-
What’s on the Outside Doesn’t Really Matter to Many Breast Cancer Survivors
-
From a Breast Cancer Survivor: A Message to Telephone and Telemarketer Solicitors
